Immatics Closes $150M Offering, Nets $161.1M With Full Underwriter Option
IMTX sits 87% above its 52-week low of $5.05 on elevated volume (2.2× avg).
Summary
Immatics closed a $150 million underwritten offering, netting $161.1 million after full exercise of the underwriters' option. The deal funds its cancer pipeline through 2028 but dilutes existing holders.
Key Events · Financing and Capital Events · IMTX
-
Offering Completed With Full Option
The sale of 15,535,100 ordinary shares at $8.69 per share plus pre-funded warrants for 4,315,304 shares at $8.689 each closed, including full exercise of the underwriters' 2,589,814-share option.
-
Net Proceeds of $161.1M
After underwriting discounts and offering expenses, the company received approximately $161.1 million in net proceeds, exceeding the $150 million gross target.
-
Pre-Funded Warrant Terms
Warrants carry a $0.001 exercise price, are immediately exercisable via cashless exercise only, do not expire, and include a 9.99% beneficial ownership blocker (adjustable to 19.99%).
-
Use of Proceeds
Funds will support continued R&D of the PRAME-targeting pipeline, manufacturing, potential commercialization, and working capital.
Analysis · IMTX · Life Sciences
The underwritten offering closed on August 26, 2026, generating approximately $161.1 million in net proceeds after the underwriters exercised their full option to purchase additional shares. Priced at $8.69 per share—a modest discount to the $9.45 price at the time of this report—the deal included pre-funded warrants for 4.3 million shares with a nominal $0.001 exercise price. The capital extends the company's runway into 2028 and funds its PRAME-focused oncology pipeline, but existing shareholders absorb dilution from roughly 19.9 million new shares and warrant-covered shares.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMTX was trading at $9.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.05 to $12.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.